 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- CHM 2101 / Chimeric Therap
A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers. (Level 1, West Hall; Poster Bd #: K23) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_397;
P1/2
Clinical Trial Registration Number: NCT06055439. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- ||| CHM 2101 / Chimeric Therap
Enrollment open: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy (clinicaltrials.gov) - May 23, 2024
P1/2, N=135, Recruiting, Sponsor: Chimeric Therapeutics
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Not yet recruiting --> Recruiting
- || CHM 2101 / Chimeric Therap
Trial completion date, Trial initiation date, Trial primary completion date: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy (clinicaltrials.gov) - Dec 21, 2023
P1/2, N=135, Not yet recruiting, Sponsor: Chimeric Therapeutics
Not yet recruiting --> Recruiting Trial completion date: Aug 2024 --> Jun 2027 | Initiation date: Feb 2024 --> Jun 2024 | Trial primary completion date: Aug 2024 --> Jun 2026
- |||| CHM 2101 / Chimeric Therap
New P1/2 trial: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy (clinicaltrials.gov) - Sep 26, 2023
P1/2, N=135, Not yet recruiting, Sponsor: Chimeric Therapeutics
- | CHM 2101 / Chimeric Therap
#Chimeric takes Initial Regulatory Step towards #IND for #CHM2101 $CHM https://t.co/jzr0M2OKIl (Twitter) - Jun 10, 2022